EUVIMEDEUVIMED entdecken
Crossref

Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK

Lucía Cea-Soriano, Mari-Ann Wallander, Luis Alberto García Rodríguez

Journal of Family Planning and Reproductive Health Care · 2016-10 · 42 (4) · 247-254

DOI: 10.1136/jfprhc-2015-101202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Family Planning and Reproductive Health Care, online erschienen am 20.04.2016. Verfasst von Lucía Cea-Soriano und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiologist, Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited data to show the levels of prescribing of combined oral contraceptives (COCs) and other hormonal products containing estrogen/progestogen combinations that may be outside the product licence.

Aims

To determine the diagnosis/indication recorded at the time of prescription of cyproterone acetate/ethinylestradiol (CPA/EE) and two COCs, levonorgestrel/EE (LNG/EE) and drospirenone/EE (DRSP/EE). Design and setting Retrospective study using a primary care database, The Health Improvement Network (THIN).

Methods

Women in THIN aged 12–49 years prescribed CPA/EE, LNG/EE or DRSP/EE in 2002–2010 were identified. Overall use of each product and proportion of new users each year were determined. Among new users, database codes were analysed to infer the reason for prescription.

Results

The proportion of new users of each product in 2002 and 2010, respectively, were: LNG/EE, 2.03% and 2.40%; CPA/EE, 0.45% and 0.27%; and DRSP/EE, 0.27% and 0.56%. Most new users prescribed CPA/EE had a record of acne (51.0% and 79.2% in 2002 and 2010, respectively) or hirsutism (3.0% and 5.0% in 2002 and 2010, respectively); the proportion of new users with a record only for contraception decreased from 32.9% in 2002 to 8.6% in 2010. Among new users prescribed DRSP/EE or LNG/EE in 2010, 43.2% and 30.8% of women, respectively, did not have a record indicating use for contraception.

Conclusions

Adherence to prescribing guidelines for CPA/EE has improved over time. A substantial proportion of women using DRSP/EE or LNG/EE had records for hormone-responsive conditions only, suggesting that many women were prescribed these therapies for non-contraceptive use.

Schlagwörter

Stichwörter der Autor:innen

cyproterone acetatedrospirenonehormonal contraceptionlevonorgestrelpharmacoepidemiologyprescribing

Autor:innen und Institutionen

  • Pharmacoepidemiologist, Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain.
  • Department of Preventive Medicine and Public Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
  • Professor, Department of Public Health and Caring Science, Uppsala University, Uppsala, Sweden.

Förderung

  • Bayer

Zitieren

APA

Cea-Soriano, L., Wallander, M. A., & García Rodríguez, L. A. (2016). Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK. Journal of Family Planning and Reproductive Health Care, 42(4), 247-254. https://doi.org/10.1136/jfprhc-2015-101202

Vancouver

Cea-Soriano L, Wallander MA, García Rodríguez LA. Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK. Journal of Family Planning and Reproductive Health Care. 2016;42(4):247-254. doi:10.1136/jfprhc-2015-101202

BibTeX
@article{CeaSoriano2016,
  author = {Cea-Soriano, Lucía and Wallander, Mari-Ann and García Rodríguez, Luis Alberto},
  title = {Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK},
  journal = {Journal of Family Planning and Reproductive Health Care},
  year = {2016},
  volume = {42},
  number = {4},
  pages = {247--254},
  doi = {10.1136/jfprhc-2015-101202}
}
Kostenlos starten →